Company Overview and News
President Trump’s protectionist agenda and the resultant trade war have made smaller caps gain an upper hand over larger cap. This is because large caps have wider foreign exposure and thus any negative development pertaining to the global economy does not bode well for this category. It is fraught with risks emanating from ongoing trade tensions, the likely strength in the greenback and a slowdown in several foreign economies.
WFCNP IYZ VZA FCOM STI-A WFC UNP IXP TGT STI RTH DG VZ
JPMorgan’s (JPM - Free Report) board of directors has announced a 42.9% hike in its quarterly dividend. The revised dividend of 80 cents per share will be paid on Oct 31 to shareholders of record as of Oct 5. Based on the last day’s closing price of $114.30 per share, the dividend yield is 2.8%. The hike comes as part of the company’s 2018 capital plan which was approved by the Federal Reserve this June.
STI UNP PNC STI-A PNUCL PNCFO
Form 424(b)(2) Filed Pursuant to Rule 424(b)(2) File No. 333-227397 Product Supplement No. EQUITY INDICES LIRN-1 (To Prospectus dated September 18, 2018 and Prospectus Supplement dated September 18, 2018)
Form 424(b)(2) Filed Pursuant to Rule 424(b)(2) File No. 333-227397 Product Supplement No. EQUITY INDICES
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Becton, Dickinson (BDX), Occidental Petroleum (OXY) and Phillips 66 (PSX). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
DB PSX UMBF BRK.A COO ALL STI STI-A OXY
Following the upbeat expectations announced at the Barclays Global Financial Services Brokers Conference on Wednesday, Citigroup’s (C - Free Report) shares rose more than 1.5% to close at $70.51. The bank’s chief financial officer, John Gerspach, announced the company’s latest outlook for the Sep-end quarter. The Wall Street biggie expects third-quarter 2018 fixed income and equity trading revenues likely to be flat to slightly higher on a year-over-year basis.
C STI CMA STI-A
2018-09-13 cnbc - 1
Kroger – The supermarket operator reported adjusted quarterly profit of 41 cents per share, 3 cents a share above estimates. Revenue was slightly short of forecasts, however. Kroger maintained its full-year adjusted earnings per share forecast of $2.00 to $2.15 per share, compared to a consensus estimate of $2.12.
STI CZR STI-A TWX PVTL TWC TLRD ADBE
U.S. equities are suffering another bout of weakness on Wednesday, falling into negative territory after a big intraday reversal pushed the Dow Jones Industrial Average back below the 26,000 level. The catalyst, as you may have guessed, was more fears on the trade front. Reports are crossing that adding Canada to the recently penned bilateral trade deal between the United States and Mexico could be more difficult than previously believed.
BPFH MBFI CHFN CFG USB CFIN BPFHW STI CIWV STI-A BPFHP STL FITB CSFL SBT
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
Silicon Investor Message Boards
This table lists all message boards related to STI / SunTrust Banks, Inc. on message board site Silicon Investor.
as of ET